Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC); R Paridaens; L Dirix; C Lohrisch; L Beex; M Nooij; D Cameron; L Biganzoli; T Cufer; L Duchateau; A Hamilton; J P Lobelle; M Piccart

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC), R Paridaens, L Dirix, C Lohrisch, L Beex, M Nooij, D Cameron, L Biganzoli, T Cufer, L Duchateau, A Hamilton, J P Lobelle, M Piccart

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stable disease with a number of hormone therapies. We explored the efficacy and safety of the steroidal aromatase inactivator exemestane as first-line hormonal therapy in MBC in postmenopausal women.

Original language	English
Pages (from-to)	1391-8
Number of pages	8
Journal	Annals of Oncology
Volume	14
Issue number	9
Publication status	Published - Sept 2003

Keywords / Materials (for Non-textual outputs)

Adult
Aged
Aged, 80 and over
Androstadienes
Antineoplastic Agents, Hormonal
Breast Neoplasms
Female
Humans
Middle Aged
Postmenopause
Tamoxifen
Treatment Outcome

Cite this

European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC), Paridaens, R., Dirix, L., Lohrisch, C., Beex, L., Nooij, M., Cameron, D., Biganzoli, L., Cufer, T., Duchateau, L., Hamilton, A., Lobelle, J. P., & Piccart, M. (2003). Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of Oncology, 14(9), 1391-8.

European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC) ; Paridaens, R ; Dirix, L et al. / Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. In: Annals of Oncology. 2003 ; Vol. 14, No. 9. pp. 1391-8.

@article{941d35b588dd423b8a04af95cbdc04eb,

title = "Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer",

abstract = "Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stable disease with a number of hormone therapies. We explored the efficacy and safety of the steroidal aromatase inactivator exemestane as first-line hormonal therapy in MBC in postmenopausal women.",

keywords = "Adult, Aged, Aged, 80 and over, Androstadienes, Antineoplastic Agents, Hormonal, Breast Neoplasms, Female, Humans, Middle Aged, Postmenopause, Tamoxifen, Treatment Outcome",

author = "{European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC)} and R Paridaens and L Dirix and C Lohrisch and L Beex and M Nooij and D Cameron and L Biganzoli and T Cufer and L Duchateau and A Hamilton and Lobelle, {J P} and M Piccart",

year = "2003",

month = sep,

language = "English",

volume = "14",

pages = "1391--8",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier",

number = "9",

}

European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC), Paridaens, R, Dirix, L, Lohrisch, C, Beex, L, Nooij, M, Cameron, D, Biganzoli, L, Cufer, T, Duchateau, L, Hamilton, A, Lobelle, JP & Piccart, M 2003, 'Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer', Annals of Oncology, vol. 14, no. 9, pp. 1391-8.

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. / European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC); Paridaens, R; Dirix, L et al.
In: Annals of Oncology, Vol. 14, No. 9, 09.2003, p. 1391-8.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

AU - European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC)

AU - Paridaens, R

AU - Dirix, L

AU - Lohrisch, C

AU - Beex, L

AU - Nooij, M

AU - Cameron, D

AU - Biganzoli, L

AU - Cufer, T

AU - Duchateau, L

AU - Hamilton, A

AU - Lobelle, J P

AU - Piccart, M

PY - 2003/9

Y1 - 2003/9

N2 - Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stable disease with a number of hormone therapies. We explored the efficacy and safety of the steroidal aromatase inactivator exemestane as first-line hormonal therapy in MBC in postmenopausal women.

AB - Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stable disease with a number of hormone therapies. We explored the efficacy and safety of the steroidal aromatase inactivator exemestane as first-line hormonal therapy in MBC in postmenopausal women.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Androstadienes

KW - Antineoplastic Agents, Hormonal

KW - Breast Neoplasms

KW - Female

KW - Humans

KW - Middle Aged

KW - Postmenopause

KW - Tamoxifen

KW - Treatment Outcome

M3 - Article

C2 - 12954578

SN - 0923-7534

VL - 14

SP - 1391

EP - 1398

JO - Annals of Oncology

JF - Annals of Oncology

IS - 9

ER -

European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC), Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of Oncology. 2003 Sept;14(9):1391-8.

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Fingerprint

Cite this